According to the OECD, Spain is in the top 10 countries with the highest development in the biotechnology sector. Although we are far from the top centres such as Boston, Silicon Valley, London or Switzerland, the news is encouraging, after a few years in which the scarce access to funding in the sector made things difficult. In the last two years we have witnessed how Spanish biotech companies are obtaining amounts of funding not seen before in the sector.
M&A advisors with expertise in the technology sector
biotechnology funding
Latest Sectoral Reports |
Last Entries
Oryzon genomics floats on the MAB
Oryzon Genomics is now listed on the MAB, reinforcing the biotech market, which is the largest listed on the MAB. Of the 33 companies listed on the MAB, 8 are active in the biotechnology sector.
France's Synerlab buys Alcalá Pharma
If a week ago we told you that Spanish biotechs were going public on the MAB, this week it is the turn of crowdfunding and acquisitions in the biotech sector.
October 2015: Funding for the biotech sector: InnoUp Farma and Oryzon Genomics and Mind The Byte
In the second half of October we have witnessed that two Spanish companies focused on cancer treatment solutions have received funding. In addition, the largest deal in Crowdequity for the biotech sector has also been closed. The protagonist of this operation has been Mind The byte.
Minoryx and Sanifit receive investment from Caixa Capital Risk to fight against rare diseases.
The biotechnology sector in general, and the rare disease sector in particular, has attracted the interest of Caixa Capital Risc, making it one of the most active investors in the sector. The latest related operations were Sanifit in November 2014, which received €3.6M from Caixa Capital Risc, and Minoryx in January 2015, which received €$1.6M.